Randomized trial demonstrates improved clinical efficacy in keratotic tinea pedis with crisaborole, highlighting treatment benefits.
Objective The clinical effectiveness of 2% crisaborole cream and amorolfine hydrochloride cream on keratinized tinea pedis is the goal of this investigation. Methods Using random numbers, 100 patients with keratotic tinea pedis were split into two groups: the observation group received 2% crisaborole ointment and amorolfine hydrochloride cream once a night for four weeks, while the control group received white vaseline and amorolfine hydrochloride cream once a night. The two groups were compared in terms of clinical efficacy, adverse reaction incidence, and improvement in the dermatological quality of life index (DLQI) score. Results Following four weeks of treatment, the observation group's overall effective rate was 98%, which was significantly higher than 82%, and the difference was statistically significant (p < 0.001). The pruritus scales were (6.12 ± 1.92) days, (12.01 ± 3.89) days, (3.92 ± 3.02) days, and (15.09 ± 3.98) days in the control group. The observation group was significantly lower than the control group at both the 2-week and 4-week treatment points (p < 0.001). The incidence of negative effects did not differ significantly between the two groups (p > 0.05). Conclusions For keratinized tinea foot, 2% crisaborole ointment can increase the effectiveness of amorolfine hydrochloride cream.
No takes yet. Share an insight, caveat, or question.
Du et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: